Last $0.96 USD
Change Today +0.021 / 2.23%
Volume 149.3K
As of 8:04 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

novabay pharmaceuticals inc (NBY) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/23/13 - $2.03
52 Week Low
11/7/13 - $0.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

novabay pharmaceuticals inc (NBY) Related Businessweek News

No Related Businessweek News Found

novabay pharmaceuticals inc (NBY) Details

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It offers Aganocide compounds, including auriclosene irrigation solution to reduce urinary catheter blockage and encrustation; an eye drop formulation of auriclosene for treating adenoviral conjunctivitis; and a gel formulation of auriclosene for treating impetigo, a highly contagious skin infection. The company also provides NeutroPhase, a skin and wound cleanser for non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

29 Employees
Last Reported Date: 03/6/14
Founded in 2000

novabay pharmaceuticals inc (NBY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $440.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $316.7K
Senior Vice President of Business & Corporate...
Total Annual Compensation: $279.1K
Compensation as of Fiscal Year 2013.

novabay pharmaceuticals inc (NBY) Key Developments

NovaBay Pharmaceuticals Announces Presentation of Positive Data from Clinical Trial of Auriclosene Irrigation Solution for Urinary Catheter Encrustation and Blockage

NovaBay(R) Pharmaceuticals, Inc. announced that Todd A. Linsenmeyer, M.D., Director of Urology, Kessler Institute for Rehabilitation, West Orange, NJ, and one of the principal investigators of a multi-center clinical study, will present results showing significant benefits from a new catheter irrigation solution. In the trial, 9 of 14 catheters collected from patients that irrigated twice a week with saline solution, the only current treatment option, became completely encrusted. In contrast, none of those treated with a new investigational product called Auriclosene Irrigation Solution (AIS) became significantly encrusted. Parallel reductions were seen in clinical catheter blockages. Dr. Linsenmeyer will describe the Phase 2 trial and its results at the annual meeting of the American Urological Association meeting, May 16-21 in Orlando, FL--the first time the data have been presented at a scientific meeting. The results represent a potentially significant step forward in the care of patients who must use urinary catheters that stay in place for days or weeks at a time--so-called indwelling catheters. Because of spinal cord injuries, multiple sclerosis, and other conditions, tens of thousands of people in the U.S. must use such catheters. The problem is that in some patients the catheter can frequently become coated with bacteria and crystalline biofilms, which can sometimes block the catheter entirely. Blockage of the catheter can cause very serious medical issues.

NovaBay Pharmaceuticals, Inc. Announces Completion of Enrollment in its Global Phase 2B Clinical Trial, BAYnovation

NovaBay Pharmaceuticals, Inc. announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation. The trial is investigating NovaBay's Auriclosene (NVC-422) Ophthalmic Solution as a treatment for adenoviral conjunctivitis, a highly contagious, potentially sight-impairing form of 'pink eye'. This condition affects millions of people globally and there is currently no approved treatment available anywhere in the world. NovaBay expects to report results from its trial in mid-2014.

NovaBay Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

NovaBay Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. The company reported sales revenue of $188,000, operating loss of $4,078,000, loss before income taxes of $3,565,000, net loss of $3,565,000 or $0.08 per basic and diluted share against sales revenue of $63,000, operating loss of $3,487,000, loss before income taxes of $4,007,000, net loss of $4,009,000 or $0.11 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBY:US $0.96 USD +0.021

NBY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NBY.
View Industry Companies

Industry Analysis


Industry Average

Valuation NBY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.5x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVABAY PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at